Literature DB >> 20526852

Resolution of Henoch-Schönlein purpura nephritis after acquired IgA deficiency.

Mototsugu Tanaka1, George Seki, Kenichi Ishizawa, Junichi Hirahashi, Kenichiro Miura, Takashi Sekine, Tomonosuke Someya, Hiroshi Hataya, Michio Nagata, Toshiro Fujita.   

Abstract

We report a case of Henoch-Schönlein purpura nephritis (HSPN) with acquired IgA deficiency due to parvovirus B19 infection. The patient was diagnosed as having Henoch-Schönlein purpura (HSP) at 6 years old, and subsequently developed macrohematuria and massive proteinuria of 7.4 g/day with decreased creatinine clearance of 70.2 ml/min/1.73 m(2) and significantly elevated serum IgA level of 449 mg/dl. The first kidney biopsy yielded the diagnosis of severe HSPN. After the initiation of the immunosuppressive therapy, the patient was infected with parvovirus B19 and developed virus-associated hemophagocytic syndrome (VAHS). Thereafter, the serum level of IgA selectively decreased and remained undetectable until the present time. Repeated kidney biopsies performed over a period of 14 years revealed a remarkable histological improvement in association with stabilization of the patient's kidney function. Considering the severity of initial kidney injury, persistent acquired IgA deficiency was likely to add favorable effects to the immunosuppressive therapy in this patient with HSPN.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20526852     DOI: 10.1007/s00467-010-1568-0

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  8 in total

1.  Microbial IgA protease removes IgA immune complexes from mouse glomeruli in vivo: potential therapy for IgA nephropathy.

Authors:  Michael E Lamm; Steven N Emancipator; Janet K Robinson; Michifumi Yamashita; Hisashi Fujioka; Jiazhou Qiu; Andrew G Plaut
Journal:  Am J Pathol       Date:  2007-12-28       Impact factor: 4.307

2.  A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group.

Authors:  N Yoshikawa; H Ito; T Sakai; Y Takekoshi; M Honda; M Awazu; K Ito; K Iitaka; Y Koitabashi; K Yamaoka; K Nakagawa; H Nakamura; S Matsuyama; Y Seino; N Takeda; S Hattori; M Ninomiya
Journal:  J Am Soc Nephrol       Date:  1999-01       Impact factor: 10.121

3.  Repeat renal biopsy in children with IgA nephropathy.

Authors:  N Yoshikawa; K Iijima; S Matsuyama; J Suzuki; A Kameda; S Okada; H Nakamura
Journal:  Clin Nephrol       Date:  1990-04       Impact factor: 0.975

4.  Acquired IgA deficiency.

Authors:  M Gleeson; R L Clancy; A W Cripps; R L Henry; M J Hensley; J H Wlodarczyk
Journal:  Pediatr Allergy Immunol       Date:  1994-08       Impact factor: 6.377

5.  Clinical outcome of Schönlein-Henoch purpura nephritis in children.

Authors:  K Schärer; R Krmar; U Querfeld; H Ruder; R Waldherr; F Schaefer
Journal:  Pediatr Nephrol       Date:  1999-11       Impact factor: 3.714

6.  Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children.

Authors: 
Journal:  Kidney Int       Date:  1978-02       Impact factor: 10.612

7.  Multiple combined therapy for severe Henoch-Schönlein nephritis in children.

Authors:  K Iijima; S Ito-Kariya; H Nakamura; N Yoshikawa
Journal:  Pediatr Nephrol       Date:  1998-04       Impact factor: 3.714

Review 8.  Understanding organ dysfunction in hemophagocytic lymphohistiocytosis.

Authors:  Caroline Créput; Lionel Galicier; Sophie Buyse; Elie Azoulay
Journal:  Intensive Care Med       Date:  2008-04-22       Impact factor: 41.787

  8 in total
  1 in total

Review 1.  Aberrantly glycosylated IgA1 as a factor in the pathogenesis of IgA nephropathy.

Authors:  Mototsugu Tanaka; George Seki; Tomonosuke Someya; Michio Nagata; Toshiro Fujita
Journal:  Clin Dev Immunol       Date:  2011-01-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.